David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Jan

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Prostate Cancer: Novel PSMA-Targeted Radioligand Shows Reduced Salivary Gland Uptake in Preclinical Studies

HCC LLM Advice and Treatment Concordance

Medical Societies Caution Misinformation May Drive Underuse of Lung Cancer Screening

Atezolizumab vs Placebo With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer

ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer